Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06718322Not ApplicableEnrolling By Invitation

PIECES - Towards Large-Scale Adaptation and Tailored Implementation of Primary Cancer Prevention Programs

Role: collaborator

NCT06878027Recruiting

Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool

Role: collaborator

NCT04712448Active Not Recruiting

Serum Prevalence of SARS-Cov-2 Antibodies in Pre-pandemic Blood Samples (SPARE)

Role: collaborator

NCT04854343Unknown

SLPI for Prostate Cancer

Role: collaborator

NCT03151421Not ApplicableCompleted

Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home

Role: collaborator

NCT03150186Unknown

Environmental Assessment of Secondhand Smoke Exposure in Private Settings and Outdoor Settings in Europe

Role: collaborator

All 6 trials loaded